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SYNTHETIC and biological materials can be used for many complex transformations in carbon management and target-oriented drug delivery systems. Carboxylation and reduction are two important reactions responsible for carbon management in nature. Eight biological pathways are known for converting inorganic carbon to organic material in cell biomass: (i) reductive pentose phosphate; (ii) Hatch-Slack cycle; (iii) Crassulacean acid metabolism; (iv) reductive citric acid; (v) 3-hydoxypropionate; (vi) dicarboxylate/4-hydroxybutyrate; (vii) 3-hydroxypropionate/4-hydroxybutyrate pathway and, (viii) reductive acetyl-CoA cycle. The first three are present in plant and some prokaryotes, 4th and 5th in bacteria, 6th and 7th in archaea and 8th in bacteria and archaea.
The choice of a carrier molecule is important in targetted drug delivery because it significantly affects pharmacodynamics and pharmacokinetics of drugs. Materials like lipids, natural and synthetic polymers, carbohydrates, surfactants and dendrimers are used as drug carriers [1] [2] [3] . The drug conjugate can be designed for improving its potential for complex - interactions towards the target moiety and drug [4] [5] [6] [7] . Biological materials are eco-friendly, but they have limitation with regard to the proposed application as they are less durable in terms of mechanical strength and resistance to corrosion. Synthetic materials, on the other hand, have issues related to environment and biocompatibility in complex transformations. Metal complexes can serve 11 . It is therefore an appealing strategy to make use of embedded metal centres as modified biological and synthetic catalysts or precursors. This communication proposes methods to fuse synthetic and biological complexes to design efficient and biocompatible materials. The proposed fusion has the advantages in the upcoming research in carbon management and target-oriented drug delivery using the benefits of both biological and synthetic materials (Figure 1) . The methods/protocols used to design embedded metal-centre catalysts for synthetic-biological fusion include the following.
(i) Axial coordination via bridging ligands can be an important strategy to connect synthetic and biological components. Axial coordination to Ni II and Zn II for trans-III cyclams is favoured in protein complexes via bridging ligands such as phthalate and is responsible for their biological activity [12] [13] [14] [15] . Metal complexes are readily available for combinatorial synthesis of metal centres and ligand exchange. There are several examples of this fusion, such as insertion of symmetric metal complexes into the active site of apomyoglobin by binding to His93, which enables these new semisynthetic metalloenzymes to catalyse enantioselective sulphoxidation using the chiral protein cavity 16 . (ii) Ligands with weak to intermediate field strength and multidenticities may be suitable to design pharmaceutically acceptable metal carriers with embedded metal centres. To make hexamine cobalt [Co(NH 3 ) 6 ] + biocompatible, the four NH 3 ligands are replaced by ligands such as N 2 O 4 or its isoelectronic moieties 17 . Furthermore, ligands with chiral centres can optimally tune the activity of metal centres towards their catalytic application in a living system 18 ; and with some exceptions, aromaticity reduces cytotoxicity 19 . (iii) Metals exert structural roles, and inert complexes can be generally biocompatible. Free ion activity controls the bioavailability of metals, and complexation restricts metal activity. Similar biological activities are found in isostructural ruthenium and osmium complexes, and confirm the structural role of metals 20 . Labile metal complexes are more bioavailable and cytotoxic compared to inert complexes. Higher metal bioavailability makes the corresponding complex less biocompatible and vice versa 8 . Complexes with heavy metals, metals from the middle of the transition series or the third row down, or rare earth elements are preferred as a synthetic complex choice.
(v) Development of multi-nuclear complexes capable of forming an adduct with biomolecules. Improved bioactivity is found in tetranuclear ruthenium complexes compared to dinuclear complexes 21 . Ligand choices for this purpose are planar aromatic amines, alkyl amines, iminoethers, chiral dienes, amino acids, carbohydrates, steroids, alkaloids, small peptides and their isoelectronic entities. The above strategies can provide the optimal ligand for making biocompatible catalysts in order to optimize carbon management (Table  1) . Synthetic-biological fusion can solve many problems in carbon sequestration by increasing the catalytic rate and/or oxygenase activity, improving plant photosynthesis, and making synthetic carbon transformations more efficient and eco-friendly.
Targeted drug delivery increases patient compliance efficiency of pharmaceutical agents through improved biodistribution and pharmacokinetics [22] [23] [24] . Syntheticbiological fusion can be used to design target-oriented drug delivery systems [4] [5] [6] [7] (Table 2 ) by selecting appropriate -cloud extension, such as estrogen moieties for targeting the breast, or xylylbicyclam, a potent anti-HIV agent that mobilizes stem cells (AMD3100, 'Mozobil') via targeting the 7-helix membrane receptor, CXCR4. Specific metallomacrocycle configurations can be recognized by proteins via metal coordination to specific amino acid side chains, H-bonding and hydrophobic interactions, allowing drug design optimization 25 . Nucleic acid (A10 RNA) ligands, aptamers and Dox which bind to the surface of prostate cancer cells have been used for targeted drug delivery 26 . The proposed fusion has the potential for scientific merger of different therapies (like Ayurvedic and allopathic medications) in cases where there is involvement of a metal either in the target or in the drug to develop effective medications with less side effects.
